Small molecule ectonucleotide pyrophosphatase/phosphodiesterase 1 inhibitors in cancer immunotherapy for harnessing innate immunity

被引：4
|
作者：
Choi, Junwon [1 ]
机构：
[1] Ajou Univ, Dept Mol Sci & Technol, Suwon, Gyeonggi, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2023年 / 44卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
cancer immunotherapy; cGAMP; ENPP1; inhibitor; innate immunity; STING; CYCLIC GMP-AMP; NUCLEOTIDE PYROPHOSPHATASE; EXTRACELLULAR CGAMP; POTENT INHIBITORS; BYSTANDER CELLS; HUMAN NPP1; DERIVATIVES; HYDROLYSIS; 2ND-MESSENGER; ENPP1;
D O I：
10.1002/bkcs.12646
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was recently identified as a major hydrolase of an endogenous stimulator of interferon genes (STING) agonist, 2 ',3 '-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). ENPP1 is a promising therapeutic target in cancer immunotherapy, in which the inhibition of ENPP1 enhances anticancer immunity via STING-mediated innate immune activation. This review highlights the role of ENPP1 in innate immunity and the recent discovery of small molecule ENPP1 inhibitors as immunomodulators in cancer immunotherapy.
引用
收藏
页码：88 / 99
页数：12
相关论文
共 50 条
  • [31] Effects of Different Variants in the ENPP1 Gene on the Functional Properties of Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1
    Stella, Jacqueline
    Buers, Insa
    van de Wetering, Koen
    Hoehne, Wolfgang
    Rutsch, Frank
    Nitschke, Yvonne
    HUMAN MUTATION, 2016, 37 (11) : 1190 - 1201
  • [32] Metabolic regulation of innate immunity in cancer immunotherapy
    Yuheng Liao
    Hui Yang
    Cancer Biology & Medicine, 2023, (12) : 898 - 902
  • [33] Metabolic regulation of innate immunity in cancer immunotherapy
    Liao, Yuheng
    Yang, Hui
    CANCER BIOLOGY & MEDICINE, 2023, 20 (12) : 898 - 902
  • [34] Association of K121Q Polymorphism in Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 with Clinical Characteristics of Metabolic Syndrom
    Li, N.
    Pan, H.
    Cui, M.
    Li, Q.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2016, 124 (05) : 313 - 317
  • [35] K121Q polymorphism in the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 gene is associated with acute kidney rejection
    Sortica, Denise A.
    Crispim, Daisy
    Bauer, Andrea C.
    Nique, Pamela S.
    Nicoletto, Bruna B.
    Crestani, Ricieli P.
    Staehler, Jennifer T.
    Manfro, Roberto C.
    Canani, Luis H.
    PLOS ONE, 2019, 14 (07):
  • [36] Discovery of Pyrido[2,3-d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment
    Sun, Yaoliang
    Chen, Manman
    Han, Yuyan
    Li, Weiqiang
    Ma, Xiaoyu
    Shi, Zihan
    Zhou, Yang
    Xu, Lan
    Yu, Lei
    Wang, Yuxiang
    Yu, Jinghua
    Diao, Xingxing
    Meng, Linghua
    Xu, Shilin
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (05) : 3986 - 4006
  • [37] Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 K173Q Polymorphism Is Associated with Diabetic Nephropathy in the Taiwanese Population
    Lin, Cheng-Chia
    Wu, Chun-Te
    Wu, Lawrence Shih-Hsin
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (04) : 239 - 242
  • [38] Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors
    Lee, Sang-Yong
    Mueller, Christa E.
    MEDCHEMCOMM, 2017, 8 (05) : 823 - 840
  • [39] Relationship between the K121Q polymorphism of ectonucleotide pyrophosphatase/phosphodiesterase 1 and obesity in children and adolescent
    Luo, Feihong
    Cao, Lingfeng
    Shen, Shuixian
    Kiess, Wieland
    HORMONE RESEARCH, 2008, 70 : 125 - 125
  • [40] Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status
    Schlicher, Lisa
    Green, Luke G.
    Romagnani, Andrea
    Renner, Florian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345